EyePoint Pharmaceuticals, Inc. (EYPT)

EyePoint Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Net Income	-78.92	-70.8	-102.25	-58.42	-45.39	-56.79
Depreciation & Amortization	0.66	0.46	2.45	2.77	2.65	2.6
Share-Based Compensation	21.71	12.06	14.18	7.45	5.55	4.57
Other Operating Activities	44.09	60.15	20.63	-1.9	22.76	-7.08
Operating Cash Flow	-12.46	1.88	-65.01	-50.1	-14.44	-56.7
Capital Expenditures	-4.19	-3.48	-2.15	-0.16	-0.36	-0.21
Change in Investments	-10.4	0.17	-15.12	-32.97	0	0
Investing Cash Flow	-14.6	-3.32	-17.27	-33.12	-0.36	-0.21
Share Issuance / Repurchase	233.86	229.55	0.4	217.2	50.21	23.04
Debt Issued / Paid	-36.66	-41.86	-0.19	-0.15	-12.63	25.94
Other Financing Activities	-4.9	-0.62	-0.89	-0.15	-0.09	-15.12
Financing Cash Flow	192.3	187.07	-0.69	216.9	37.49	33.86
Exchange Rate Effect	0	0	0	0	0	0
Net Cash Flow	165.25	185.63	-82.96	133.68	22.7	-23.05
Free Cash Flow	-16.65	-1.61	-67.16	-50.25	-14.8	-56.91
Free Cash Flow Margin	-33.30%	-3.49%	-162.19%	-136.04%	-42.97%	-279.46%
Free Cash Flow Per Share	-0.32	-0.04	-1.80	-1.75	-1.15	-5.46

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).